We are pleased to share the published this morning on the analysis of the first data from our phase 3 trial of the PREMIER study in CMT1A.
Early indicators suggest results requiring more in-depth and comprehensive analysis but confirm the high safety profile of the product.
Considering these initial results, Pharnext plans to continue analyzing the data, this analysis will help determine the next steps toward potential marketing authorization.